On August 2 and 8, 2017, Keshava Katti and Kian Croston ran two ticket assays to determine the effect of adjusting plasmid DNA proportionality. The past two tickets contained equal proportions of PcArsR and PARsGFP (1:1 ratio).
The Cadets2Vets team set up two tickets, positive and negative tests, on August 2. The positive ticket tested the dosage response at varied volumes of arsenic water; the negative ticket substituted all instances of arsenic water with molecular water.
Column 1: 2 µL Master Mix + 2 µL water (molec/arsenic)
Column 2: 2 µL Master Mix + 4 µL water (molec/arsenic)
Column 3: 2 µL Master Mix + 6 µL water (molec/arsenic)
Column 4: 2 µL Master Mix
Positive Master Mix contained: 12 µL S30 Extract 16 µL S30 Promega 4 µL amino (-Cys) 0.8 µL amino (-Leu) 3.2 µL arsenic water 4 µL of PcArsR + Ars1.1 circuit plasmid | Negative Master Mix contained: 12 µL S30 Extract 16 µL S30 Promega 4 µL amino (-Cys) 0.8 µL amino (-Leu) 3.2 µL molecular water 4 µL of PcArsR + Ars1.1 circuit plasmid |
The image (above) shows the results of our tickets. As expected, our control ticket with no arsenic displayed no GFP expression. On the other hand, our positive ticket showed the same lack of fluorescence, which was attributed to the excess regulatory protein. Unfortunately, the Cadets2Vets team did not realize that Ars1.1 was actually causing increased production of regulatory protein until after our fourth ticket assay on August 8.
Team Cadets2Vets created 8uL of PcArsR + Ars1.1 plasmid DNA by combining 5.33 µL of Ars1.1 and 2.67 µL of PcArsR (2:1 ratio, respectively). There was a fundamental misunderstanding behind this combination. Our team believed that Ars1.1 was our GFP-producing plasmid DNA; in reality, Ars1.1 was our constitutive promoter, producing our ArsR regulatory protein, and GFP plasmid DNA combined.
The original idea was to increase the amount of promoter binding sites for ArsR, which is how GFP expression is regulated in the arsenic circuit. The additional PArsGFP plasmid was supposed to prevent ArsR from being free in solution and binding to free arsenic ions, thereby unintentionally sequestering our arsenic ions and ArsR proteins away from the regulatory mechanism we designed. Instead, we accidentally ended up increasing the amount of constitutive promoter DNA (Ars1.1 added unwanted constitutive promoter DNA), thereby increasing the overall production of ArsR regulatory protein.